Phluence vs TailorMed (2026)
Both work the gap between a prescription being written and a patient actually taking the medicine, and they are paid by different parties, which changes everything about how to read them. Phluence automates the post prescription access journey for pharmaceutical manufacturers, targeting the abandonment point where prior authorisation, benefits and affordability defeat a therapy start. TailorMed identifies financially at risk patients and matches them to assistance programmes, sold to providers and pharmacies, so its incentive is the patient affording their care rather than a particular product being dispensed. Both are legitimate and they are not interchangeable. The question neither answers is what the patient is told at first contact, because in this workflow a patient frequently cannot tell whether the person helping them works for their clinic or for the company that makes the drug.
- It automates the post prescription access journey for pharmaceutical manufacturers, which is a different buyer and a different economics from provider side tooling.
- The agentic approach targets the specific point where prescriptions are abandoned, between the prescription being written and the medicine reaching the patient.
- For a manufacturer, closing that gap is directly measurable in therapy starts rather than in staff hours saved.
- It identifies financially at risk patients and matches them against a large network of assistance programmes, which is provider side work aimed at the patient's ability to pay rather than at the manufacturer's conversion rate.
- The buyer is the health system or pharmacy, so the incentive is aligned with the patient completing therapy affordably rather than with a specific product being dispensed.
- Financial navigation reaches patients across therapies rather than following one manufacturer's medicine.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Phluence and TailorMed are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Phluence | TailorMed |
|---|---|---|
| Primary category | Healthcare Administrative Automation | Healthcare Administrative Automation |
| Founded | 2015 | 2016 |
| Headquarters | San Francisco, California | New York, New York, United States |
| Website | phluence.com | tailormed.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Phluence its top capability grade on AI Centrality and Setting and Specialty Coverage. Set against TailorMed, Phluence grades higher on several axes, including AI Centrality, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index records no top capability grade for TailorMed on any axis it scores. Set against Phluence, TailorMed grades higher on Autonomy and Oversight Model, Security Certifications and Trust Center and EHR and Interoperability Depth. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Phluence or TailorMed?
On the axes where the AI Health Index separates them, Phluence grades higher on several axes, including AI Centrality, Model Supply Chain Disclosure and AI Safety and PHI Stewardship, and TailorMed grades higher on Autonomy and Oversight Model, Security Certifications and Trust Center and EHR and Interoperability Depth. Phluence leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Phluence and TailorMed differ most?
The widest separation the AI Health Index records between Phluence and TailorMed is on AI Centrality, where Phluence grades A and TailorMed grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Phluence and TailorMed grade the same?
The AI Health Index grades Phluence and TailorMed the same on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and HIPAA and BAA Posture. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Phluence and TailorMed not disclosed?
At the last review, at least one of Phluence and TailorMed published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the RCM & Prior Auth AI page.
The buyer difference is the whole governance question here and it should be stated rather than implied: a platform paid by a pharmaceutical manufacturer to improve access to that manufacturer's product has an interest in which therapy the patient ends up on, while a platform paid by a provider to find financial assistance does not. Neither vendor publishes how that interest is managed, what data flows back to the manufacturer, or what the patient is told about who is contacting them.
Neither publishes pricing. Ask both what disclosure the patient receives at first contact, because in this workflow the patient often cannot tell whether the caller works for their clinic or for a drug company.